NYSEARCA:XBISPDR S&P Biotech ETF Stock Price, Forecast & News

SPDR S&P Biotech ETF's stock was trading at $79.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XBI shares have increased by 31.8% and is now trading at $104.11. View which stocks have been most impacted by Coronavirus.

SPDR S&P Biotech ETF announced a quarterly dividend on Friday, December 20th. Investors of record on Monday, December 23rd will be given a dividend of $0.0009 per share on Thursday, December 26th. This represents a $0.00 dividend on an annualized basis and a dividend yield of 0.00%. The ex-dividend date of this dividend is Friday, December 20th. View SPDR S&P Biotech ETF's dividend history.

Media stories about XBI stock have trended somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. SPDR S&P Biotech ETF earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the exchange traded fund a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the near term. View the latest news aboutSPDR S&P Biotech ETF.

Based on aggregate information from My MarketBeat watchlists, some companies that other SPDR S&P Biotech ETF investors own include iShares Nasdaq Biotechnology ETF (IBB), NVIDIA (NVDA), Netflix (NFLX), Walt Disney (DIS), Intel (INTC), Alibaba Group (BABA), Gilead Sciences (GILD), Micron Technology (MU), Cisco Systems (CSCO) and Pfizer (PFE).

SPDR S&P Biotech ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "XBI."

SPDR S&P Biotech ETF's stock is owned by many different retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (20.93%), Morgan Stanley (17.79%), Healthcare of Ontario Pension Plan Trust Fund (4.89%), Wells Fargo & Company MN (1.90%), SG Americas Securities LLC (1.24%) and Two Sigma Advisers LP (0.90%).

XBI stock was sold by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, Wells Fargo & Company MN, Two Sigma Advisers LP, HBK Investments L P, Orbimed Advisors LLC, Thrivent Financial for Lutherans, Chatham Capital Group Inc., and Carnegie Capital Asset Management LLC.

XBI stock was bought by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, SG Americas Securities LLC, tru Independence LLC, Meitav Dash Investments Ltd., Advisor Group Holdings Inc., Private Advisor Group LLC, and CMH Wealth Management LLC.

Shares of XBI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBI stock can currently be purchased for approximately $104.11.

SPDR S&P Biotech ETF has a market capitalization of $4.71 billion.

The official website for SPDR S&P Biotech ETF is www.spdrs.com.

SPDR S&P Biotech ETF's mailing address is One Lincoln Street, Boston, 02111, United States. The exchange traded fund can be reached via phone at +1-866-7872257.